CHRN
ChronoScale Corporation
There isn't enough reported data to score CHRN yet.
MSFT
Microsoft Corporation
MSFT's fundamentals are strong and it looks cheap: trading at 27x earnings, below its usual 34x. Analysts expect strong earnings growth.
CHRN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
CHRN's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
MSFT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Healthy | |
| Strong |
MSFT's revenue, profitability, cash flow and balance sheet are all currently healthy.
CHRN PE Valuation
CHRN has no meaningful PE right now: it lost money over the past year.
MSFT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 25x | $523 | — |
| Cheap | 27x | $525 | +0.4% |
| Current | 27x | $523 | — |
| Fair | 34x | $652 | +25% |
| Expensive | 37x | $711 | +36% |
Historical ranges are pointers, not guarantees.
MSFT's PE is in its cheap range at 27x. If earnings grow as analysts expect, today's price would be 25x next year's earnings.
CHRN Forward outlook
There aren't enough analyst estimates for CHRN to show an outlook.
MSFT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Stable | |
| Moderate | |
| High |
Analysts expect strong earnings and revenue growth for MSFT, with profitability holding steady.
CHRN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2026 | -$6.83 | +$0.40 |
| Q4 2025 | -$6.59 | +$1.84 |
| Q3 2025 | -$5.56 | +$4.19 |
| Q2 2025 | -$6.52 | +$5.33 |
| Q1 2025 | -$7.23 | +$7.32 |
| Q4 2024 | -$8.43 | +$8.07 |
| Q3 2024 | -$9.75 | +$7.05 |
| Q2 2024 | -$11.85 | +$6.30 |
MSFT has the stronger earnings trend. Trailing diluted EPS is down 194% for CHRN versus MSFT up 36%.
MSFT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $20.79 | +8.6% |
| Q3 2026 | $19.15 | +36% |
| Q2 2026 | $17.95 | +32% |
| Q1 2026 | $16.80 | +30% |
| Q4 2025 | $15.99 | +29% |
| Q3 2025 | $14.06 | +16% |
| Q2 2025 | $13.64 | +16% |
| Q1 2025 | $12.93 | +12% |
| Q4 2024 | $12.41 | +12% |
MSFT's earnings per share have climbed steadily: $19.15 over the past year, up 36% from the year before, and higher year over year for 14 quarters in a row.
CHRN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $41.5M | +881% |
| Q1 2026 | $2.1M | -37% |
| Q4 2025 | $3.1M | -38% |
| Q3 2025 | $4.2M | +2.4% |
| Q2 2025 | $2.1M | -58% |
| Q1 2025 | $3.4M | -10% |
| Q4 2024 | $5.1M | +5% |
| Q3 2024 | $4.1M | -10% |
CHRN's revenue is growing: $41M last quarter, up 1917% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -60% | +133 points |
| Q1 2026 | -262% | -161 points |
| Q4 2025 | -144% | -100 points |
| Q3 2025 | -33% | +31 points |
| Q2 2025 | -193% | -146 points |
| Q1 2025 | -102% | -15 points |
| Q4 2024 | -44% | +27 points |
| Q3 2024 | -64% | -0.3 points |
CHRN's operating margin was −60% last quarter, up 133 points from the same quarter a year ago.
MSFT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $92.3B | +19% |
| Q2 2026 | $90B | +18% |
| Q1 2026 | $82.9B | +18% |
| Q4 2025 | $81.3B | +17% |
| Q3 2025 | $77.7B | +18% |
| Q2 2025 | $76.4B | +18% |
| Q1 2025 | $70.1B | +13% |
| Q4 2024 | $69.6B | +12% |
MSFT has the edge over CHRN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 50% | +0.9 points |
| Q2 2026 | 45% | +0.2 points |
| Q1 2026 | 46% | +0.7 points |
| Q4 2025 | 47% | +1.6 points |
| Q3 2025 | 49% | +2.3 points |
| Q2 2025 | 45% | +1.8 points |
| Q1 2025 | 46% | +1.1 points |
| Q4 2024 | 45% | +1.9 points |
MSFT has the edge over CHRN on profitability, with a higher operating margin.
CHRN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $11.6M | +$13.6M |
| Q1 2026 | -$2.1M | -$148K |
| Q4 2025 | -$4.5M | -$3M |
| Q3 2025 | -$2.1M | +$212K |
| Q2 2025 | -$3.5M | -$814K |
| Q1 2025 | -$2M | +$1.5M |
| Q4 2024 | -$1.5M | +$173K |
| Q3 2024 | -$2.3M | +$1.1M |
CHRN has the edge over MSFT on cash flow, with more consistent year-over-year improvement.
MSFT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $18.6B | -27% |
| Q2 2026 | $19.6B | -23% |
| Q1 2026 | $15.8B | -22% |
| Q4 2025 | $5.9B | -9.3% |
| Q3 2025 | $25.7B | +33% |
| Q2 2025 | $25.6B | +9.6% |
| Q1 2025 | $20.3B | -3.2% |
| Q4 2024 | $6.5B | -29% |
MSFT's free cash flow has been positive every quarter for seven years: $60B over the past year, down 23% from the year before.
CHRN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3981% | +142M shares |
| 1 year | +8489% | +144M shares |
| 3 years | +16727% | +145M shares |
| 5 years | +34737% | +145M shares |
CHRN has 145M diluted shares, up 8489% from a year ago.
MSFT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -7M shares |
| 1 year | -0.3% | -20M shares |
| 3 years | -0.2% | -16M shares |
| 5 years | -1.6% | -121M shares |
| Available history | -3.2% | -245M shares |
MSFT has the edge over CHRN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $4.4B |
| Q2 2026 | $4.6B |
| Q1 2026 | $4.6B |
| Q4 2025 | $7.4B |
| Q3 2025 | $5.7B |
| Q2 2025 | $4.5B |
| Q1 2025 | $4.8B |
| Q4 2024 | $5B |
MSFT spent $21B buying back its own shares over the past year, up 5.2% from the year before.
CHRN Net Leverage
CHRN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MSFT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | 0.1x | Very low |
MSFT's net debt is less than a year of its operating earnings (EBITDA).
CHRN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.3 | Neutral |
| Stochastic | 8.3 | Oversold |
CHRN's weekly RSI is 37 (neutral) and its Stochastic is 8 (oversold).
MSFT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 62.1 | Neutral |
| Stochastic | 68.0 | Neutral |
MSFT's weekly RSI is 62 (neutral) and its Stochastic is 68 (neutral).
CHRN PE vs Technology Sector
CHRN has no meaningful PE right now: it lost money over the past year.
MSFT PE vs Technology Sector
| Metric | MSFT | Sector median | Relative |
|---|---|---|---|
| PE | 27x | 28x | 2% below |
| PE % | 16 | 35 | 19 pts below |
MSFT is trading at 27x earnings, in line with the Technology sector's median of 28x.
CHRN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $15.4 | 30% below |
| 20 week MA | $18.8 | 42% below |
| 50 week MA | $14.5 | 25% below |
| 100 week MA | $10.1 | 7.5% above |
| 200 week MA | $14.9 | 27% below |
CHRN's trend is mixed: it's above one of its five weekly moving averages, and 27% below its 200-week average.
MSFT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $524.7 | 0.3% below |
| 20 week MA | $484.8 | 7.9% above |
| 50 week MA | $446.9 | 17% above |
| 100 week MA | $453.8 | 15% above |
| 200 week MA | $411.5 | 27% above |
MSFT has the edge over CHRN on trend strength, trading above more of its moving averages.
CHRN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $78.8 | $104.7 | +33% |
| 2021 | $104.7 | $45.3 | -57% |
| 2022 | $45.3 | $18.6 | -59% |
| 2023 | $18.6 | $37.5 | +102% |
| 2024 | $37.5 | $9.74 | -74% |
| 2025 | $9.74 | $5.56 | -43% |
| 2026 YTD | $5.56 | $10.9 | +95% |
CHRN has the edge over MSFT on returns for 2026, with the stronger performance.
MSFT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $159.0 | $222.8 | +40% |
| 2021 | $222.8 | $334.7 | +50% |
| 2022 | $334.7 | $238.7 | -29% |
| 2023 | $238.7 | $376.0 | +58% |
| 2024 | $376.0 | $430.5 | +14% |
| 2025 | $430.5 | $487.7 | +13% |
| 2026 YTD | $487.7 | $523.0 | +7.2% |
MSFT has finished higher in five of the last six years, two of them by more than 50%. It's up 7.2% so far in 2026.